- Home
- PHIO vs CLRB Comparison
PHIO vs CLRB Comparison
Compare PHIO & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHIO | CLRB |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 12.9M |
| IPO Year | 2011 | 2008 |
Fundamental Metrics
Financial Performance| Metric | PHIO | CLRB |
|---|---|---|
| Price | $1.21 | $2.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $10.67 | N/A |
| AVG Volume (30 Days) | ★ 7.5M | 28.9K |
| Earning Date | 06-17-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.81 | $0.23 |
| 52 Week High | $4.19 | $10.19 |
Technical Indicators
Market Signals| Indicator | PHIO | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 56.30 | 41.00 |
| Support Level | $1.03 | $2.55 |
| Resistance Level | $1.43 | $3.60 |
| Average True Range (ATR) | 0.11 | 0.25 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 55.39 | 17.24 |
Price Performance
Historical ComparisonAbout PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.